Mumbai, July 23, 2025 Specialty chemical manufacturer Rossari Biotech reported a 4% year-on-year decline in its Q1 FY26 net profit, with earnings falling from ₹34.90 crore in Q1 FY25 to ₹33.60 crore in the latest quarter. Despite the dip in profit, the company showcased healthy revenue growth, highlighting resilience amid a challenging economic landscape.
💬 Leadership Speaks:
In a joint statement, Edwar Meneses, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said:
“Despite the evolving market dynamics, we’ve delivered a stable performance in Q1 FY26. Growth in our Home, Personal Care & Performance Chemicals (HPPC) and Animal Health & Nutrition (AHN) segments reflects the strength of our strategic focus. While exports saw a slight decline, our domestic business continues to remain strong, thanks to our product mix and operational initiatives.”
📈 Segment Performance & Future Outlook
The HPPC segment registered a solid 16% growth, while AHN followed closely with 12% growth.
The company is doubling down on capacity expansion, supply chain enhancements, and targeting high-growth sectors such as agrochemicals, personal care, pharmaceuticals, and oil & gas.
With new investments and commissioning underway, Rossari aims to improve operational agility and boost future profitability.
🏭 About Rossari Biotech
Headquartered in Mumbai, Rossari Biotech is a leading provider of specialty chemicals across sectors like textiles, home care, personal care, animal nutrition, and industrial performance. The company operates strategically located manufacturing units in Silvassa and Dahej, enabling efficient service to domestic and international markets.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
The global PFAS testing market is experiencing rapid transformation, driven by increasing regulatory scrutiny and public concern over per- and… Read More
The global Cell and Gene Solutions Market is experiencing transformative growth, projected to soar significantly between 2025 and 2034. Fueled… Read More
Asia-Pacific is poised to become the fastest-growing region in the small-scale bioreactors market over the coming years, driven by several… Read More
North America continues to dominate the global neurostimulation devices market, holding a significant 60% share in 2024. Several key factors… Read More
AAVnerGene Inc., an innovative biotech company based in Rockville, MD, known for its cutting-edge AAV tissue-targeted delivery and manufacturing technologies,… Read More
Jiangsu Hengrui Pharmaceuticals Co., Ltd. and IDEAYA Biosciences, Inc. are set to showcase their groundbreaking research at the IASLC 2025… Read More